CONTEXT: We previously used positron emission tomography (PET) measurement of brain metabolism with 18fluorodeoxyglucose to show that patients receivingselective serotonin reuptake inhibitors (SSRIs) who have a tryptophan depletion-induced return of depressive symptoms have an acute decrease in metabolism in orbitofrontal cortex, dorsolateral prefrontal cortex, and thalamus. Many patients with depression in remission while taking norepinephrine reuptake inhibitors (NRIs) (but not SSRIs) experience a return of depressive symptoms with depletion of norepinephrine and dopamine using alpha-methylparatyrosine (AMPT). OBJECTIVE: To assess brain metabolic correlates of AMPT administration in patients with depression in remission while receiving NRIs. DESIGN, SETTING, AND PARTICIPANTS: Randomized, controlled, double-blind trial in which 18 patients recruited in 1997-2000 from the general community who had depression in remission while taking NRIs had PET imaging in a psychiatric research unit following AMPT and placebo administration. INTERVENTIONS: After initial medication with desipramine and follow-up until response, patients underwent active AMPT (five 1-g doses administered orally over 28 hours) and placebo (diphenhydramine hydrochloride, five 50- mg doses administered similarly) catecholamine depletion challenges in randomized order of assignment, after which PET imaging was performed on day 3 of each condition. Both study conditions were performed 1 week apart. MAIN OUTCOME MEASURES: Regional brain metabolism rates in patients with and without AMPT-induced return of depressive symptoms. RESULTS:AMPT-induced return of depressive symptoms was experienced by 11 of the 18 patients and led to decreased brain metabolism in a number of cortical areas, with the greatest magnitude of effects in orbitofrontal (P =.002) and dorsolateral prefrontal (P =.03) cortex and thalamus (P =.006). Increased resting metabolism in prefrontal and limbic areas predicted vulnerability to return of depressive symptoms. CONCLUSIONS: Different neurochemical systems that mediate depression may have effects on a common brain circuitry. Baseline metabolism in successfully treated depressed patients may predict vulnerability to future episodes of depression.
RCT Entities:
CONTEXT: We previously used positron emission tomography (PET) measurement of brain metabolism with 18fluorodeoxyglucose to show that patients receiving selective serotonin reuptake inhibitors (SSRIs) who have a tryptophan depletion-induced return of depressive symptoms have an acute decrease in metabolism in orbitofrontal cortex, dorsolateral prefrontal cortex, and thalamus. Many patients with depression in remission while taking norepinephrine reuptake inhibitors (NRIs) (but not SSRIs) experience a return of depressive symptoms with depletion of norepinephrine and dopamine using alpha-methylparatyrosine (AMPT). OBJECTIVE: To assess brain metabolic correlates of AMPT administration in patients with depression in remission while receiving NRIs. DESIGN, SETTING, AND PARTICIPANTS: Randomized, controlled, double-blind trial in which 18 patients recruited in 1997-2000 from the general community who had depression in remission while taking NRIs had PET imaging in a psychiatric research unit following AMPT and placebo administration. INTERVENTIONS: After initial medication with desipramine and follow-up until response, patients underwent active AMPT (five 1-g doses administered orally over 28 hours) and placebo (diphenhydramine hydrochloride, five 50- mg doses administered similarly) catecholamine depletion challenges in randomized order of assignment, after which PET imaging was performed on day 3 of each condition. Both study conditions were performed 1 week apart. MAIN OUTCOME MEASURES: Regional brain metabolism rates in patients with and without AMPT-induced return of depressive symptoms. RESULTS:AMPT-induced return of depressive symptoms was experienced by 11 of the 18 patients and led to decreased brain metabolism in a number of cortical areas, with the greatest magnitude of effects in orbitofrontal (P =.002) and dorsolateral prefrontal (P =.03) cortex and thalamus (P =.006). Increased resting metabolism in prefrontal and limbic areas predicted vulnerability to return of depressive symptoms. CONCLUSIONS: Different neurochemical systems that mediate depression may have effects on a common brain circuitry. Baseline metabolism in successfully treated depressedpatients may predict vulnerability to future episodes of depression.
Authors: E Mervaala; J Föhr; M Könönen; M Valkonen-Korhonen; P Vainio; K Partanen; J Partanen; J Tiihonen; H Viinamäki; A K Karjalainen; J Lehtonen Journal: Psychol Med Date: 2000-01 Impact factor: 7.723
Authors: A L Brody; S Saxena; P Stoessel; L A Gillies; L A Fairbanks; S Alborzian; M E Phelps; S C Huang; H M Wu; M L Ho; M K Ho; S C Au; K Maidment; L R Baxter Journal: Arch Gen Psychiatry Date: 2001-07
Authors: M S George; T A Ketter; P I Parekh; N Rosinsky; H A Ring; P J Pazzaglia; L B Marangell; A M Callahan; R M Post Journal: J Neuropsychiatry Clin Neurosci Date: 1997 Impact factor: 2.198
Authors: H S Mayberg; M Liotti; S K Brannan; S McGinnis; R K Mahurin; P A Jerabek; J A Silva; J L Tekell; C C Martin; J L Lancaster; P T Fox Journal: Am J Psychiatry Date: 1999-05 Impact factor: 18.112
Authors: U D McCann; D Thorne; M Hall; K Popp; W Avery; H Sing; M Thomas; G Belenky Journal: Neuropsychopharmacology Date: 1995-08 Impact factor: 7.853
Authors: Ronald C Kessler; Patricia Berglund; Olga Demler; Robert Jin; Doreen Koretz; Kathleen R Merikangas; A John Rush; Ellen E Walters; Philip S Wang Journal: JAMA Date: 2003-06-18 Impact factor: 56.272
Authors: Gregor Hasler; Stephen Fromm; Paul J Carlson; David A Luckenbaugh; Tracy Waldeck; Marilla Geraci; Jonathan P Roiser; Alexander Neumeister; Noah Meyers; Dennis S Charney; Wayne C Drevets Journal: Arch Gen Psychiatry Date: 2008-05
Authors: Fernando Caravaggio; Lawrence S Kegeles; Alan A Wilson; Gary Remington; Carol Borlido; David C Mamo; Ariel Graff-Guerrero Journal: Synapse Date: 2016-07-11 Impact factor: 2.562
Authors: Katalin Marthi; Steen Jakobsen; Dirk Bender; Søren B Hansen; Stefan Bo Smith; Flemming Hermansen; Raben Rosenberg; Donald F Smith Journal: Psychopharmacology (Berl) Date: 2004-07 Impact factor: 4.530
Authors: Dara M Cannon; Jacqueline M Klaver; Summer A Peck; Denise Rallis-Voak; Kristine Erickson; Wayne C Drevets Journal: Neuropsychopharmacology Date: 2008-10-22 Impact factor: 7.853